Xeris Biopharma Holdings, Inc.

XNASHealth care

Last traded price · USD

$10.46

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $10.46
Volume: —
Day's high: —
Day's low: —

In brief

Xeris Biopharma Holdings, Inc. is a health care company listed on Nasdaq, valued at about $1.91B.
Its shares closed at $10.46 on 4 Nov 2026, up 5.7% over the past year.
From India you can buy XERS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Xeris Biopharma Holdings, Inc. (XERS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole XERS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade XERS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +3.9% (SPY −1.6%, XLV +13.5%). 3 months: +29.0% (SPY −0.4%, XLV +15.5%). 1 year: +5.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: XERS, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $10.46 was 11.2% above its 50-day average ($9.40) and 38.7% above its 200-day average ($7.54). It has closed above the 200-day for 95 sessions, since 23 Jun 2026. The 50-day average crossed above the 200-day on 20 Jul 2026, 76 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
85% of the way up its 52-week range
Closed at $10.46 on 4 Nov 2026: 8.4% below the 52-week high of $11.42 (19 Oct 2026) and 99.2% above the low of $5.25 (25 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 4.4% of shares outstanding
8.0M shares were sold short at the 15 Oct 2026 settlement, 4.4% of the 182.3M shares outstanding; covering them would take 3.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+3.9%

6 months+64.2%

1 year+5.7%

5 years+439.2%

Newswire

About

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Website

Notable moves

November 6, 2025
−21.88%
May 16, 2022
+29.24%
December 31, 2021
+20.58%

Newswire

About

Website

Notable moves

November 6, 2025
−21.88%
May 16, 2022
+29.24%
December 31, 2021
+20.58%

Xeris Biopharma Holdings, Inc.

XNASHealth care

Last traded price · USD

$10.46

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $10.46
Volume: —
Day's high: —
Day's low: —

In brief

Xeris Biopharma Holdings, Inc. is a health care company listed on Nasdaq, valued at about $1.91B.
Its shares closed at $10.46 on 4 Nov 2026, up 5.7% over the past year.
From India you can buy XERS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Xeris Biopharma Holdings, Inc. (XERS) shares from India?

Do I need the price of a whole XERS share to invest?

How much can I invest in US stocks in a year?

Can I trade XERS options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: +3.9% (SPY −1.6%, XLV +13.5%). 3 months: +29.0% (SPY −0.4%, XLV +15.5%). 1 year: +5.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: XERS, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $10.46 was 11.2% above its 50-day average ($9.40) and 38.7% above its 200-day average ($7.54). It has closed above the 200-day for 95 sessions, since 23 Jun 2026. The 50-day average crossed above the 200-day on 20 Jul 2026, 76 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
85% of the way up its 52-week range
Closed at $10.46 on 4 Nov 2026: 8.4% below the 52-week high of $11.42 (19 Oct 2026) and 99.2% above the low of $5.25 (25 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 4.4% of shares outstanding
8.0M shares were sold short at the 15 Oct 2026 settlement, 4.4% of the 182.3M shares outstanding; covering them would take 3.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+3.9%

6 months+64.2%

1 year+5.7%

5 years+439.2%

Newswire

About

Website

Notable moves

November 6, 2025
−21.88%
May 16, 2022
+29.24%
December 31, 2021
+20.58%

Newswire

About

Website

Notable moves

November 6, 2025
−21.88%
May 16, 2022
+29.24%
December 31, 2021
+20.58%

Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

85% of the way up its 52-week range

Short interest at 4.4% of shares outstanding

Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. in brief

Behind SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

85% of the way up its 52-week range

Short interest at 4.4% of shares outstanding